Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in TP53-mutated acute myeloid leukemia
Mapping exactly how TP53-mutated leukemias resist treatment reveals specific vulnerabilities researchers can now design combination therapies to target.
This Moffitt Cancer Center review comprehensively catalogs the mechanisms driving BCL-2 inhibitor resistance in TP53-mutated AML, from lineage plasticity to metabolic reprogramming. It proposes targeted strategies to overcome each resistance pathway in this poor-prognosis population.
What the study was
- Study design
- Narrative review
- Population
- TP53-mutated AML patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Frontiers in Cell and Developmental Biology
Why it surfaced
Highly relevant review of venetoclax resistance in TP53-mutated AML from Moffitt. Practical framework for clinicians but no novel primary data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.